These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18251696)

  • 1. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.
    Grijalva CG; Griffin MR
    Expert Rev Vaccines; 2008 Feb; 7(1):83-95. PubMed ID: 18251696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.
    Grijalva CG; Poehling KA; Nuorti JP; Zhu Y; Martin SW; Edwards KM; Griffin MR
    Pediatrics; 2006 Sep; 118(3):865-73. PubMed ID: 16950975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
    Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
    Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The epidemiology of childhood pneumococcal disease in the United States in the era of conjugate vaccine use.
    Toltzis P; Jacobs MR
    Infect Dis Clin North Am; 2005 Sep; 19(3):629-45. PubMed ID: 16102653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis.
    Pavia M; Bianco A; Nobile CG; Marinelli P; Angelillo IF
    Pediatrics; 2009 Jun; 123(6):e1103-10. PubMed ID: 19482744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Conjugate pneumococcal vaccines and influence on the ear, nose and throat area].
    Almaç A; Kuru FD
    Kulak Burun Bogaz Ihtis Derg; 2011; 21(6):345-8. PubMed ID: 22014302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based impact of pneumococcal conjugate vaccine in young children.
    Poehling KA; Lafleur BJ; Szilagyi PG; Edwards KM; Mitchel E; Barth R; Schwartz B; Griffin MR
    Pediatrics; 2004 Sep; 114(3):755-61. PubMed ID: 15342850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia.
    Jardine A; Menzies RI; Deeks SL; Patel MS; McIntyre PB
    Pediatr Infect Dis J; 2009 Sep; 28(9):761-5. PubMed ID: 19546840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving microbiology and molecular epidemiology of acute otitis media in the pneumococcal conjugate vaccine era.
    Pichichero ME; Casey JR
    Pediatr Infect Dis J; 2007 Oct; 26(10 Suppl):S12-6. PubMed ID: 18049375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
    Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children.
    Shields B
    J Pediatr Health Care; 2001; 15(4):203-8; quiz 209-10. PubMed ID: 11462129
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.
    Adam D; Fehnle K
    Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.
    Nelson JC; Jackson M; Yu O; Whitney CG; Bounds L; Bittner R; Zavitkovsky A; Jackson LA
    Vaccine; 2008 Sep; 26(38):4947-54. PubMed ID: 18662735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New pneumococcal vaccine].
    Gaudelus J
    Bull Acad Natl Med; 2003; 187(8):1477-86; discussion 1486-8. PubMed ID: 15146579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The heptavalent pneumococcal conjugate vaccine immunization project by Bangkok Metropolitan in Thai infants.
    Liulak W; Thisyakorn U
    J Med Assoc Thai; 2010 Nov; 93 Suppl 5():S13-5. PubMed ID: 21298831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives.
    Bechini A; Boccalini S; Bonanni P
    Vaccine; 2009 May; 27(25-26):3285-90. PubMed ID: 19200829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
    Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
    Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.